FORTE BIOSCIENCES, INC. Proceeds from Sale and Maturity of Marketable Securities
FORTE BIOSCIENCES, INC. (FBRX) reported Proceeds from Sale and Maturity of Marketable Securities of $12.72 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-04-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2020-04-23
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2020-03-31 was $12.72M, a 54.30% decline year-over-year.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2019-12-31 was $16.84M, a 12.94% decline year-over-year.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2019-09-30 was $27.69M, a 21.82% increase year-over-year.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2019-06-30 was $21.11M, a 21.56% increase year-over-year.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2019 was $93.47M, a 36.41% increase from fiscal 2018.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2018 was $68.52M, a 56.72% increase from fiscal 2017.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2017 was $43.73M, a 9.09% decline from fiscal 2016.
- FORTE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2016 was $48.09M, a 36.80% increase from fiscal 2015.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2020-03-31 | $12.72M 10-Q · filed 2020-04-23 | $29.56M derived: sum of 2 quarters · filed 2020-04-23 | $57.25M derived: sum of 3 quarters · filed 2020-04-23 | $78.36M derived: sum of 4 quarters · filed 2020-04-23 |
| 2019-12-31 | $16.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $44.53M derived: sum of 2 quarters · filed 2020-02-27 | $65.64M derived: sum of 3 quarters · filed 2020-02-27 | $93.47M 10-K · filed 2020-02-27 |
| 2019-09-30 | $27.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $48.80M derived: sum of 2 quarters · filed 2019-11-12 | $76.64M 10-Q · filed 2019-11-12 | $95.98M derived: sum of 4 quarters · filed 2020-04-23 |
| 2019-06-30 | $21.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $48.95M 10-Q · filed 2019-08-08 | $68.28M derived: sum of 3 quarters · filed 2020-04-23 | $91.02M derived: sum of 4 quarters · filed 2020-04-23 |
| 2019-03-31 | $27.84M 10-Q · filed 2020-04-23 | $47.17M derived: sum of 2 quarters · filed 2020-04-23 | $69.91M derived: sum of 3 quarters · filed 2020-04-23 | $87.27M derived: sum of 4 quarters · filed 2020-04-23 |
| 2018-12-31 | $19.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $42.07M derived: sum of 2 quarters · filed 2020-02-27 | $59.44M derived: sum of 3 quarters · filed 2020-02-27 | $68.52M 10-K · filed 2020-02-27 |
| 2018-09-30 | $22.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $40.10M derived: sum of 2 quarters · filed 2019-11-12 | $49.19M 10-Q · filed 2019-11-12 | $60.26M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $17.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $26.45M 10-Q · filed 2019-08-08 | $37.53M derived: sum of 3 quarters · filed 2020-02-27 | $47.13M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $9.09M 10-Q · filed 2019-05-07 | $20.16M derived: sum of 2 quarters · filed 2020-02-27 | $29.76M derived: sum of 3 quarters · filed 2020-02-27 | $39.26M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $11.07M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $20.68M derived: sum of 2 quarters · filed 2020-02-27 | $30.17M derived: sum of 3 quarters · filed 2020-02-27 | $43.73M 10-K · filed 2020-02-27 |
| 2017-09-30 | $9.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $19.10M derived: sum of 2 quarters · filed 2018-11-08 | $32.65M 10-Q · filed 2018-11-08 | $44.08M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $23.05M 10-Q · filed 2018-08-09 | $34.48M derived: sum of 3 quarters · filed 2019-02-27 | $46.55M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $13.55M 10-Q · filed 2018-05-11 | $24.98M derived: sum of 2 quarters · filed 2019-02-27 | $37.05M derived: sum of 3 quarters · filed 2019-02-27 | $53.31M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $11.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $23.50M derived: sum of 2 quarters · filed 2019-02-27 | $39.76M derived: sum of 3 quarters · filed 2019-02-27 | $48.09M 10-K · filed 2019-02-27 |
| 2016-09-30 | $12.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $28.33M derived: sum of 2 quarters · filed 2017-11-08 | $36.66M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $16.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $24.60M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $8.33M 10-Q · filed 2017-05-23 | |||
| 2015-12-31 | $35.16M 10-K · filed 2018-03-09 |